In the prostate cancer therapy application the major expected benefits of the ExAblate treatment are:
- Low complication rate - Non-invasive treatment, patients back to their life within a day or two - Non-ionized radiation - Single session therapy - Real time MR thermometry monitoring that is used to control treatment outcome during treatment
"We are very pleased to have been the first facility to adopt the ExAblate system for Phase 1 prostate cancer clinical trials." said principle investigator Professor S.V. Kanaev, Chairman of Radiation Oncology, N.N Petrov Research Institute of Oncology. "We have had excellent results with ExAblate in treating patients suffering from bone metastases and we believe it has tremendous potential in treating prostate cancer patients with a low complication rate. We and our patients have been very pleased with the results achieved to date."
InSightec will shortly be expanding the prostate clinical trials to additional leading sites globally.
InSightec Ltd. is a privately-held company owned by Elbit Imaging, General Electric, MediTech Advisors, LLC and employees. It was founded in 1999 to develop the breakthrough MR guided Focused Ultrasound technology and transform it into the next generation operating room. Headquartered near Haifa, Israel, the company has over 160 employees and has invested more than $130 million in research, development, and clinical investigations. Its U.S. headquarters are located in Dallas, Texas. For more information, please go to: http://www.insightec.com/
ExAblate is an Image Guided, Non-invasive, Robotic Acoustic Surgery
system. The ExAblate system is the first to use the MR guided focused
ultrasound technology that combines MRI - to vi
|SOURCE InSightec Ltd|
Copyright©2010 PR Newswire.
All rights reserved